The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

被引：58

作者：

Marty, Michel ^{[1
]}

Pivot, Xavier ^{[2
]}

机构：

[1] St Louis Univ Hosp, Ctr Therapeut Innovat Oncol & Haematol, F-75010 Paris, France

[2] Univ Hosp J Minjoz, Dept Oncol, Besancon, France

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 07期

关键词：

angiogenesis; vascular endothelial growth factor (VEGF); breast cancer; bevacizumab; tyrosine kinase inhibitor; monoclonal antibody;

D O I：

10.1016/j.ejca.2008.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：912 / 920

页数：9

共 78 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] The vascular endothelial growth factor family; proteins which guide the development of the vasculature [J].

Achen, MG ;

Stacker, SA .

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 1998, 79 (05) :255-265

[3] Cellular abnormalities of blood vessels as targets in cancer [J].

Baluk, P ;

Hashizume, H ;

McDonald, DM .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :102-111

[4] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[5]

Bianchi G, 2005, EJC SUPPL, V3, P78

[6]

Borgström P, 1999, ANTICANCER RES, V19, P4203

[7]

Borgstrom P, 1996, CANCER RES, V56, P4032

[8]

Bouvet M, 1998, CANCER RES, V58, P2288

[9] EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].

BROWN, LF ;

BERSE, B ;

JACKMAN, RW ;

TOGNAZZI, K ;

GUIDI, AJ ;

DVORAK, HF ;

SENGER, DR ;

CONNOLLY, JL ;

SCHNITT, SJ .

HUMAN PATHOLOGY, 1995, 26 (01) :86-91

[10]

Burstein HJ, 2005, BREAST CANCER RES TR, V94, pS6

← 1 2 3 4 5 6 7 8 →